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Abstract Low M r phosphotyrosine protein phosphatase (LMW- 
PTP) is a 18 kDa cytosolic enzyme widely distributed in eukar- 
yotic cells. LMW-PTP catalyses the hydrolysis of phosphoty- 
rosine residues and overexpression of the enzyme in normal and 
transformed cells inhibits cell proliferation. Site directed muta- 
genesis, together with crystallographic studies, have contributed 
to clarify the catalytic mechanism, which involves the active site 
signature sequence Ci2XXXXXRts , a main feature of all PTPase 
family members. In order to identify the LMW-PTP substrate/s 
we have expressed in NIH-3T3 cells a catalytically inert Cys 12 
to Ser phosphatase mutant which has preserved its capacity for 
substrate binding. Overexpression of the mutant phosphatase 
leads to enhanced cell proliferation and serum induced mitogene- 
sis, indicating that the mutation results in the production of a 
dominant negative protein. Analysis of mutant LMW-PTP ex- 
pressing cells has enabled us to demonstrate an association be- 
tween LMW-PTP and platelet derived growth factor receptor 
that appears to be highly specific. Our data suggest a catalytic 
action of LMW-PTP on the phosphorylated platelet derived 
growth factor receptor. 
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1. Introduction 
The phosphorylation that occurs on protein tyrosine residues 
plays a critical role in the regulation of various fundamental 
biological processes uch as cell division, differentiation, and 
transformation [1]. Until recently, it was generally thought hat 
protein tyrosine kinases (PTKs) play the main role in the regu- 
lation of protein phosphorylation levels, while phosphotyrosine 
protein phosphatases (PTPases) were considered to play 
'housekeeping' roles, since they cause the dephosphorylation f 
tyrosine-phosphorylated proteins returning the kinase target 
substrates back to the basal evels. However, this point of view 
is now debated, since there are evidences that PTKs and 
PTPases cooperate in the control of cellular phosphorylation 
levels [2]. The main family of PTPases includes more than 40 
different enzymes that have been cloned and characterized [3]. 
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They share a common evolutionary conserved polypeptide 
stretch of about 250 residues that includes a strictly conserved 
CXXXXXR active site motif [3]. Both cysteine and arginine 
included in the motif are essential for catalysis. Dixon et al. [2,3] 
demonstrated that the active site cysteine forms a thiol phos- 
phate transient intermediate during the catalytic process, 
whereas the arginine plays a role both in the substrate binding 
and in the stabilisation of the transition state. The active site 
motif folds in a three-dimensional phosphate binding site as 
demonstrated byX-ray crystal structure determined by Barford 
et al. [4] for human placenta PTP1B. On the other hand, the 
CXXXXXR motif is contained also in two additional phos- 
phatase subfamilies, i.e. the dual specificity protein phos- 
phatases and the low Mr protein phosphatase. The crystal 
structure of the LMW-PTP has been recently determined [5]. 
Although this enzyme shows no general homology with respect 
to the main PTPase family members, it forms a three-dimen- 
sionally folded phosphate binding loop that is structurally iden- 
tical to that contained in the human placenta PTPIB and 
Yersinia PTPases, both included in the main PTPase family 
[4,6]. 
LMW-PTP is able to dephosphorylate phosphotyrosine con- 
taining protein in vitro [7]. Some interesting phenotype effects, 
due to the enzyme overexpression i normal and oncogene- 
transformed animal cells in culture, have been previously ob- 
served. In particular, we demonstrated that overexpression f
a synthetic gene coding for the LMW-PTP causes a general 
decrease in PDGF stimulated thymidine incorporation and 
growth rate in both normal and oncogene-transformed cells, as 
well as the decrease in the ability of transformed cells to growth 
in soft-agar [8,9]. However, we think that the overexpression 
of an active enzyme in the cells can cause several perturbations 
of the cellular environment, such as possible unusual enzyme 
localisation and above all lack of substrate specificity, thus 
leading to 'pharmacological' effects. To overcome this point, 
it was decided to use, in similar experiment, a LMW-PTP mu- 
tant where Cys ~ is replaced by Set: we demonstrated that the 
mutation of this residue, included in the phosphate binding 
loop, causes the complete loss of catalytic activity, whereas the 
protein is still able to bind substrates [10,11,12]. 
Overexpression f this mutant in cultured animal cells could 
produce a dominant negative ffect, since the overexpressed 
catalytically inactive enzyme could compete with the natural 
one for substrate binding, causing accumulation of unhydro- 
lyzed tyrosine-phosphorylated LMW-PTP substrate(s). This 
could enable us to observe phenotype ffects and to im- 
munoprecipitate he catalytically inactive enzyme-substrate 
complexes. 
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On the other hand, we think that the limited overexpression 
of a catalytically inactive nzyme gives a lower perturbation of 
the cell, enabling us to identify LMW-PTP target protein sub- 
strate(s). 
2. Materials and methods 
2.1. Materials 
Unless otherwise specified all reagents were obtained from Sigma. 
pSVT7 and pSV2neo eukaryotic expression vectors were gifts from G. 
Bensi (Biocine, Siena, Italy); restriction and modification enzymes were 
from Promega; Sequenase 2.0 DNA sequencing kit was from USBC. 
NIH-3T3 cells were purchased from ATCC; human recombinant 
platelet derived growth factor BB (PDGF-BB), human recombinant 
epidermal growth factor (EGF) and bovine insulin were from Pepro- 
tech; RC20 antiphosphotyrosine antibodies were from Affiniti; En- 
hanced Chemio-Luminescence Kit was from Amersham. [3H]Thymid- 
ine was from NEN. Anti platelet derived growth factor receptor 
(PDGF-R) antibodies were from Santa Cruz. 
2.2. Plasmid construction 
The SphI/Sacl fragment of pGEMPTPC12S [10] was subcloned in 
the EcoRI/SacI sites of pSVT7 eukaryotic expression vector. The pres- 
ence of C12S mutation was confirmed by DNA sequencing according 
to Sanger. 
2.3. Antibodies generation 
Antiserum to LMW-PTP was obtained by immunising rabbits with 
LMW-PTP, expressed as glutathione S-transferase fusion protein in E. 
eoli with the use of pGEX-KT vector (Pharmacia). The product was 
purified by means of affinity chromatography and cleaved with bovine 
thrombin (Sigma) according to Taddei et al. [13]. 
2.4. Cell culture and transfections 
NIH-3T3 cells were routinely cultured in DMEM additioned with 
10% fetal calf serum (FCS) in 5% CO2 humidified atmosphere. 10/2g 
pSVT7PTPC12S or pSVT7PTP and 0.5 pg pSV2neo (conferring neo- 
mycin resistance) were co-transfected in NIH-3T3 cells using the cal- 
cium phosphate method. Stable transfected clonal cell lines were iso- 
lated by selection in G418 (400/.tg/ml). Control cell lines were obtained 
by transfection of 2 pg pSV2neo alone. The clonal lines were screened 
for expression of the transfected genes by: (a) Northern blot analysis; 
and (b) EL1SA using polyclonal anti-LMW-PTP rabbit antibodies, 
which do not crossreact with murine ndogenous NIH-3T3 LMW-PTP. 
2.5. Growth kinetics experiments 
Two independent LMW-C12SPTP overexpressing clones were cho- 
sen for growth-determination experiments; 2 x 104 cells of each clonal 
line were seeded in 24-multiwell plates, serum starved for 24 h and then 
20% FCS was added to stimulate mitogenesis: 1 h pulses with 1 pCi/ml 
of [3H]thymidine (NEN) were performed uring a period of 24 h. 
Incorporation rate in serum-stimulated cells were normalised on the 
basis of cell number per well. Growth kinetics experiments were per- 
formed seeding 2 x |04 cells in 24-multiwell plates and counting them 
in triplicate at 24 h intervals for a total period of 72 h. 
2.6. Immunoprecipitations a d Western blot analysis 
1 x 106 cells were seeded in 10 cm plates in DMEM supplemented 
with 10% FCS. Cells were serum starved for 24 h before receiving the 
appropriate mitogenesis stimulating agent (20% FCS, PDGF-BB 50 
ng/ml, bovine insulin 300 nM or EGF 100 ng/ml) for 5 rain at 37°C. 
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Fig. 1. Phenotypic analysis of NIH-3T3 transfected clones~ (A) [3H]Thymidine incorporation i NIH-3T3-C12SPTP, NIH-3T3-wtPTP and NIH- 
3T3neo transfected clones. 1 pCi/ml of [3H]thymidine was added for 1 h to culture medium after 20% FCS refeeding of serum starved cells. Data 
obtained measuring [3H]thymidine incorporation were normalised to the number of cells per well. (B) Growth kinetic analysis of NIH-3T3-C 12SPTP, 
NIH-3T3-wtPTP and NIH-3T3neo transfected clones. Cells were seeded in DMEM supplemented with 10% FCS; exponentially growing populations 
were counted in triplicate at 24 h intervals. Data shown are relative to one experiment representative of three that gave qualitatively identical results; 
S.D. is indicated (n = 4). 
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Cells were then lysed for 20 min in ice in 700 pl of lysis buffer (50 mM 
HEPES, pH 7.5, 150 mM NaCI, 1% Triton X-100, 10% glycerol, 1.5 
mM MgCI2, 1 mM EDTA, 10 mM sodium pyrophosphate, 0.1 mM 
sodium orthovanadate, 100 mM NaF, 1 mM phenylmethanesulph- 
onylfluoride, 1 mg/ml bovine serum albumin, 10 ,ug/ml, aprotinin, 10 
/zg/ml eupeptin). Lysates were clarified by centrifugation and im- 
munoprecipitated for 4 h at 4°C with 10/lg of polyclonal nti-LMW- 
PTP antibodies or 1 ~tg anti-PDGF receptor antibodies. Immune com- 
plexes were collected on protein G Sepharose (Pharmacia), separated 
by SDS/PAGE, and transferred onto nitrocellulose (Sartorius). Im- 
munoblot was incubated in 1% bovine serum albumin in 10 mM Tris- 
HC1, pH 7.5, 1 mM EDTA, 0.1 mM sodium orthovanadate and 0.l% 
Tween-20, for 20 min at 37°C and then probed with 0.1 pg/ml of 
monoclonal RC20 anti-phosphotyrosine a tibody (Affiniti) for 20 rain 
at 37°C, washed three times in 10 mM Tris-HC1, pH 7.5, 1 mM EDTA 
and 0.5% Tween-20 and developed with Enhanced Chemio-Lumines- 
cence kit (Amersham). 
3. Results and discussion 
3.1. Analysis of dominant negative phenotypic effects 
LMW-PTP appears to be involved in the regulation of 
growth factor dependent mitogenesis showing a decrease of 
fetal calf serum and PDGF [14] stimulated DNA synthesis in 
wild-type LMW-PTP transfected cells (NIH-3T3-wtPTP). In 
order to assess whether the inactive phosphatase mutant 
(LMW-C12SPTP) was able to behave as a dominant negative 
enzyme, we have evaluated the ability of serum to stimulate 
DNA synthesis n transfected cells overexpressing the mutated 
LMW-PTP (NIH-3T3-C12SPTP). For this purpose we have 
selected several transfected clones and among them, by mean 
of ELISA, we have chosen two independent LMW-CI2SPTP 
overexpressing clones, C12S-c1.14 and cl.22, together with a 
clone (wt-cl.2) overexpressing the wt-LMW-PTP. All these 
clones showed high levels of recombinant protein expression 
(data not shown), about 15-fold with respect to basal evels [14]. 
The two LMW-C 12SPTP overexpressing clones howed a clear 
increase in DNA synthesis rate with respect o the control ine 
(NIH-3T3neo) and in contrast o an evident decrease in the 
NIH-3T3-wtPTP clones, as demonstrated by[3H]thymidine in- 
corporation i  serum-stimulated 24 h serum-starved cells (Fig. 
1A). Furthermore, analysis of growth kinetics in asynchronous 
cells was performed in transfected clones during a period of 72 
h, showing anet increase of cell number in NIH-3T3-C 12SPTP- 
c114 and cl,22 in comparison to control cell lines NIH-3T3neo 
and NIH-3T3-wtPTP (Fig. 1B). We emphasize that while over- 
expression of the active form of the enzyme within the cell 
might lead to pharmacological effects, due to the possible loss 
of substrate specificity and/or to a shift in intracellular location, 
the dominant negative approach engenders far less perturba- 
tion of the cell system, limiting itself to a variation of the level 
of specific substrate(s) of the enzyme. These considerations 
allow us to confirm that there is a stringent relationship be- 
tween the observed phenotypic modification of NIH-3T3- 
CI2SPTP cells and the interaction of LMW-C12SPTP with 
specific substrates. 
3.2. Immunologic evidence for a LMW-PTP/PDGF receptor 
interaction 
In order to find phosphorylated proteins, possibly associated 
to LMW-PTP, immunoprecipitation was performed on NIH- 
3T3-C12SPTP, NIH-3T3-wtPTP and NIH-3T3-neo cells using 
anti-LMW-PTP antibodies: after FCS stimulation, a 190 kDa 
protein was recognised by anti-phosphotyrosine antibodies 
only in the first two cell lines, but its amount was found to be 
several time higher in NIH-3T3-C12SPTP cells as compared to 
NIH-3T3-wtPTP cells (Fig. 2A). Because of the important role 
of tyrosine phosphorylation in the regulation of growth factor- 
dependent mitogenesis, we have tested the hypothesis that p 190 
could be a phosphorylated growth factor receptor. Serum 
starved NIH-3T3-C12SPTP cells were stimulated with three 
known NIH-3T3 mitogenic growth factors [15] such as EGF, 
PDGF and insulin. Fig. 2B shows that p190 is present in im- 
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Fig. 2. Association of LMW-PTP with phosphotyrosine phosphorylated proteins: Lysates from 1 × 10 6 cells were immunoprecipitated with 10 pg 
of anti-LMW-PTP polyclonal antibodies, lmmunoprecipitates w re run on SDS-PAGE, transferred tonitrocellulose membrane and probed with 
antiphosphotyrosine a tibodies. (A) Phosphotyrosine mmunoblotting of 20% FCS stimulated NIH-3T3-C12SPTP (lane 1), NIH-3T3-wtPTP (lane 
2) and NIH-3T3-neo cells (lane 3). (B) Phosphotyrosine mmunoblotting of NIH-3T3-C 12SPTP cells stimulated with different growth factors. Lane 
1 = non-stimulated cells; lane 2 = PDGF-BB; lane 3 = EGF; lane 4 = insulin; lane 5 = A431, 170 kDa EGF-receptor verexpressing cells as a positive 
phosphotyrosine control. 
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Fig. 3. Identification of p190 as PDGF receptor. (A) Lysates from 1 x 106 cells were immunoprecipitated with 10 pg of anti-LMW-PTP polyclonal 
antibodies. Immunoprecipitates were run on SDS-PAGE, transferred to nitrocellulose membrane and probed with anti PDGF-R polyclonal 
antibodies; lane 1 = NIH-3T3-CI2SPTP; lane 2 = NIH-3T3-wtPTP. (B) In an experiment similar to that of panel A, cells were immunoprecipitated 
with 1 ,ug of anti-PDGF receptor antibodies and immunoprecipitates were probed with anti-LMW-PTP polyclonal ntibodies; lanes 1 and 2 = un- 
stimulated NIH-3T3-wtPTP and NIH-3T3-C12SPTP; lanes 3 and 4 = NIH-3T3-wtPTP and NIH-3T3-C12SPTP stimulated with 50 ng/ml of 
PDGF-BB. 
munoprecipitate only after PDGF stimulation but after EGF 
or insulin treatments, as well as in non stimulated cells. These 
data led us to the hypothesis that p190 and PDGF receptor are 
identical. 
Immunoprecipitates of NIH-3T3-C12SPTP and NIH-3T3- 
wtPTP cellular lysates with anti-PTPase antibodies were im- 
munoblotted with anti-PDGR-R antibodies: the result (Fig. 
3A) confirmed that p190 is actually PDGF-R. Furthermore, we 
immunoprecipitated lysates of PDGF stimulated/unstimulated 
NIH-3T3-C12 SPTP and NIH-3T3-wtPTP cells with anti- 
PDGF-R antibodies. Fig. 3B shows a Western blot of the im- 
munoprecipitates r vealed by anti- PTPase antibodies. The for- 
mation of LMW-PTP/PDGF-R complex was observed only in 
stimulated cells, in both NIH-3T3-C12SPTP and N1H-3T3- 
wtPTP, although in the former case the phenomenon was quan- 
titatively higher. This difference in the amount of immunopre- 
cipitate (lane 3 and 4) is not a consequence of different levels 
of overexpression, which resulted to be comparable in both 
NIH-3T3-CI2SPTP and NIH-3T3-wtPTP cells as indicated by 
anti-LMW-PTP ELISA quantification (see previous section). 
This fact indicates that this phosphatase binds only to the 
activated receptor form. In NIH-3T3-C12SPTP cells the over- 
expressed inactive enzyme and the cellular wild-type enzyme 
compete for the natural substrate, resulting in a reduction of 
the hydrolysis rate of phosphorylated substrate, with its conse- 
quent concentration i crease. Both Fig. 3A and B show that 
using NIH-3T3-C12SPTP cells the amount of immunoprecipi- 
tated complex is several times higher than in NIH-3T3-wtPTP 
cells, suggesting that the interaction only occurs via the cata- 
lytic site as also suggested by the lack of SH2 domains in the 
LMW-PTR Hence, these experimental data indicate that 
PDGF-R is a specific in vivo LMW-PTP substrate. 
The interaction of SH2-domain-containing PTPase subfam- 
ily, such as PTP1C [16] and PTP1D [17,18] with activated 
PDGF-R can result in either an increase of their catalytic activ- 
ity [19] or in a change of intracellular location mediated in both 
cases by PTPases tyrosine phosphorylation. Interestingly, 
phosphorylated PTP 1D remains unable to dephosphorylate the 
activated receptor and, conversely, phosphorylated PTP1C dis- 
plays a promiscuous activity on autophosphorylated PDGF, 
EGF, insulin and insulin-like receptors, showing no substrate 
specificity [19]. For this reason we investigated the possible 
LMW-PTP modification due to PDGF-R interaction. Im- 
munoprecipitation with anti-LMW-PTP antibodies on cellular 
lysates from NIH-3T3-wtPTP cells and NIH-3T3-CI2SPTP 
cells were analysed by antiphosphotyrosine immunoblotting 
with negative results in both samples: we can conclude that in 
the case of LMW-PTP, we found that association of LMW- 
PTP with PDGF-R was not correlated with LMW-PTP tyro- 
sine phosphorylation (data not shown). 
PDGF-R activation leads to tyrosine phosphorylation of
several receptor substrates, such as: PLC-y, PI-3kinase, 
PTP1D, Src, GAP, etc., [20]. Furthermore, protein interaction 
with PDGF-R can result in the positioning of an adaptor mol- 
ecule (such as Grb2) leading to the activation of side signal 
pathways [21,22]. Finally, it is also possible that the generation 
of the mitogenic signal by PDGF-R is regulated via interactions 
modifying its kinase activity. While very little is known about 
PDGF-R direct inactivation, it recently appeared that ligand 
mediated endocytosis could be triggered by autophosphory- 
lation of PDGF-R Tyr 579 [23]. On the other hand, auto- 
phosphorylated receptor tyrosine kinases could be directly 
down-regulated by a simple dephosphorylation f specific 
phosphotyrosine residues, operated by a phosphotyrosine pro- 
tein phosphatase, which is, in turn, recruited by the receptor 
itself [1]. Our data suggest that LMW-PTP tightly interacts with 
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activated PDGF-R.  This interaction is apparantly performed 
via its catalytic site, acting on phosphotyrosine r sidues of the 
receptor cytoplasmic domain. This leads to receptor inactiva- 
tion, thus reducing the mitogenic signal, which could be consis- 
tent with the phenotypic effects observed in wild-type and 
LMW-C12SPTP transfected cells, as well as in PDGF stimu- 
lated cells overexpressing the active enzyme [14]. Hence, LMW- 
PTP appears to be involved in the negative control of PDGF-R 
mediated signals, rather than in their amplification such as in 
the case of PTPID [24,25]. Furthermore, specific dephos- 
phorylation of one of the nine known phosphotyrosine residues 
in the activated receptor could result in the specific interruption 
of only one of the side signal pathways dependent on recruit- 
ment of SHz-proteins following receptor activation. 
These experiments demonstrate PDGF-R to be the first iden- 
tified in vivo substrate of a member of the PTPase family. They 
also provide the first evidence of an alternative way to turn off 
the mitogenic signal via a Tyr-phosphorylated activated kinase 
cascade, promoted by a specific phosphatase directed dephos- 
phorylation. 
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